Modeling dynamic changes in type 1 diabetes progression: quantifying β-cell variation after the appearance of islet-specific autoimmune responses

Mathematical Biosciences and Engineering

Volumn 6, Issue 4, 2009, Pages 753-778

  Nelson, Patrick ^a   Smith, Noah ^a   Ciupe, Stanca ^b   Zou, Weiping ^a   Omenn, Gilbert S ^c   Pietropaolo, Massimo ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

cell variation; Islet marker antibodies; Mathematical modeling; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; GLUCOSE; INSULIN; PANCREAS ISLET CELL ANTIBODY;

ANIMAL; ARTICLE; AUTOIMMUNITY; BIOLOGICAL MODEL; HUMAN; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; MATHEMATICAL PHENOMENA; METABOLISM; MOUSE; PANCREAS ISLET BETA CELL; PATHOLOGY; REGULATORY T LYMPHOCYTE;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; GLUCOSE; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MATHEMATICAL CONCEPTS; MICE; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES, REGULATORY;

ANIMALIA;

EID: 76549117468     PISSN: 15471063     EISSN: 15510018     Source Type: Journal    
DOI: 10.3934/mbe.2009.6.753     Document Type: Article

References (89)

1. T. J. Orchard, J. Dorma, R. Maser, D. Becker, A. Drash, D. Ellis, R. LaPorte and L. Kuller, Prevalence of complications in IDDM by sex and duration. Pittsburgh epidemiology of diabetes complications study II, Diabetes, 39 (1990), 1116-1124.
2. R. LaPorte, M. Matsushima and Y. Chang, Prevalence and incidence of insulin-dependent diabetes, In Diabetes in America, NIDDK Publication, 95 (1995), 37-46.
3. G. Eisenbarth, Type 1 Diabetes mellitus: a chronic autoimmune disease, NEJM, 314 (1986), 1360-1368.
4. Q. Tang and J. Bluestone, Regulatory T-cell physiology and application to treat autoimmunity, Immunol. Rev., 212 (2006), 217-237.
5. T. Brusko, A. Putnam and J. Bluestone, Human regulatory T cells: role in autoimmune disease and therapeutic opportunities, Immunol. Rev., 223 (2008), 371-390
6. J. Bluestone and R. von Boehmer, Regulatory T cells, Semin. Immunol., 18 (2006), 103-110.
7. J. Todd, N. Walker, J. Cooper, D. Smyth, K. Downes, V. Plagnol, R. Bailey, S. Nejentsev, S. Field, F. Payne, C. Lowe, J. Szeszko, J. Hafler, L. Zeitels, J. Yang, A. Vella, S. Nutland, H. Stevens, H. Schuilenburg and G. Coleman, Robust associations of four new chromosome regions, from genome-wide analyses of type 1 diabetes, Nat. Genet., 39 (2007), 857-864.
8. H. Hakonarson, S. Grant, J. Bradfield, L. Marchand, C. Kim, J. Glessner, R. Grabs, T. Casalunovo, S. Taback, E. Frackelton, M. Lawson, L. Robinson, R. Skraban, Y. Lu, R. Chiavacci, C. Stanley, S. Kirsch, E. Rappaport, J. Orange and D. Monos, A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene, Nature, 448 (2007), 591-594.
9. J. Todd, J. Bell and H. McDevitt, HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus, Nature, 329 (1987), 599-604.
10. P. Morel, J. Dorman, J. Todd, H. McDevitt and M. Trueco, Aspartic acid at position 57 of the HLA-DQ beta chain protects against Type I diabetes: A family study, Proc. Natl. Acad. Sci. USA, 85 (1988), 8111-8115.
11. C. Greenbaum, D. Schatz, D. Cuthbertson, A. Zeidler, G. Eisenbarth and J. Krischer, Islet cell antibody-positive relatives with human leukocyte antigen DQA1*0102 DQB*10602: Identification by the diabetes prevention trial-type 1, J. Clin. Endocrinol. Metab., 85 (2000), 1255-1260.
12. M. Atkinson and G. Eisenbarth, Type 1 Diabetes: New perspectives on disease pathogenesis and treatment, Lancet, 358 (2001), 221-229.
13. A. Rossini, Autoimmune diabetes and the circle of tolerance, Diabetes, 53 (2004), 267-275.
14. E. Masteller, Q. Tang and J. Bluestone, Antigen-specific regulatory T cells - ex vivo expansion and therapeutic potential, Semin. Immunol., 18 (2006), 103-110.
15. N. Phillips, N. Giannoukakis and M. Trueco, Dendritic cell mediated therapy for immunoregulation of type 1 diabetes mellitus, Pediatr. Endo. Rev., 5 (2008), 873-879.
16. N. Giannoukakis, B. Phillips and M. Trueco, Toward a cure for type 1 diabetes mellitus: diabetes-suppressive dendritic cells and beyond, Pediatr. Diabetes, 9 (2008), 4-13.
17. C. Verge, R. Gianani, E. Kawasaki, L. Yu, M. Pietropaolo, R. Jackson, P. Chase and G. Eisenbarth, Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies, Diabetes, 45 (1996), 926-933.
18. C. Verge, R. Gianani, E. Kawasaki, L. Yu, M. Pietropaolo, H. Chase and G. S. Eisenbarth, Number of autoantibodies (against insulin, GAD or ICA12/IA2) rather than particular autoantibody specificities determines risk of type 1 diabetes, J. Autoimmun., 7 (1996), 379-383.
19. P. Nelson, J. Mittler and A. Perelson, Effect of drug efficacy and the eclipse phase of the viral life cycle on estimates of HIV-1 viral dynamic parameters, J. AIDS, 26 (2001), 405-412.
20. M. Nowak, S. Bonhoffer, A. Hill, R. Boehme, H. Thomas and H. McDade, Viral dynamics in hepatitis B virus infection, Proc. Natl. Acad. Sci. USA, 93 (1996), 4398-4402.
21. A. Perelson and P. Nelson, Mathematical models of HIV dynamics in vivo, SIAM Review, 41 (1999), 3-44.
22. S. Ciupe, R. Ribeiro, P. Nelson, G. Dusheiko and A. Perelson, The role of cells refractory to productive infection in acute hepatitis B viral dynamics, Proc. Natl. Acad. Sci. USA, 104 (2007), 5050-5055.
23. A. Bauer, T. Jackson and Y. Jiang, A cell-based model exhibiting branching and anstomosis during tumor-induced angiogenesis, Biophys. J., 92 (2007), 1-17.
24. T. Jackson, S. Lubkin, N. Siemers, O. Kerr, P. Senter and J. Murray, Mathematical and Experimental analysis of localization of anti-tumor antibody enzyme conjugates, B. J. of Cancer, 80 (1999), 1747-1753.
25. J. Keener and A. Panfilov, A biophysical model for defibrillation of cardiac tissue, Biophys. J., 71 (1996), 1335-1345.
26. B. Topp, K. Promislow, G. deVries, R. Miura and D. Finegood, A Model of beta-cell mass, insulin, and glucose kinetics: Pathways to Diabetes, J. Theor. Biol., 206 (2000), 605-619.
27. D. Freiesleben, P. Bak, F. Pociot, A. Karlsen and J. Nerup, Onset of type 1 diabetes: A dynamical instability, Diabetes, 48 (1999), 1677-1685.
28. R. Bergman, R. Prager, A. Volund and J. Olefsky, Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp, J. Clin. Invest., 79 (1987), 790-800.
29. R. Bergman, Y. Ider, C. Bowden and C. Cobelli, Quantitative assessment of insulin sensitivity, Am. J. Physiol., 236 (1979), E667-E677.
30. A. DeGaetano and O. Arino, Mathematical modeling of the intravenous glucose tolerance test, J. Math. Biol., 40 (2000), 136-168.
31. J. Li and Y. Kuang, Analysis of a model of the glucose-insulin regulatory system with two delays, SIAM J. Appl. Math., 67 (2007), 757-776.
32. Y. Chen, S. Wang and A. Sherman, Identifying the targets of the amplifying pathway for insulin secretion in pancreatic beta-cells by kinetic modeling of granule exocytosis, Biophys. J., 95 (2008), 2226-2241.
33. J. Li and Y. Kuang, Systemically modeling the dynamics of plasma insulin in subcutaneous injection of insulin analogues for type 1 diabetes, Math. Biosci. Eng., 6 (2009), 41-58.
34. R. Bertram, J. Previte, A. Sherman, T. Kinard and L. Satin, The phantom burster model for pancreatic beta-cells, Biophys. J., 79 (2000), 2880-2892.
35. R. Bertram, L. Satin, M. Zhang, P. Smolen and A. Sherman, Calcium and glycolysis mediate multiple bursting modes in pancreatic islets, Biophys. J., 87 (2004), 3074-3087.
36. C. Nunemaker, R. Bertram, A. Sherman, K. Tsaneva-Atanosova, C. Daniel and L. Satin, Glucose modulates Ca2+ oscillations in pancreatic islets via ionic and glycolytic mechanisms, Biophys. J., 91 (2006), 2082-2096.
37. J. M. Mahafly and L. Edelstein-Keshet, Modeling cyclic waves of circulating T cells in autoimmune diabetes, SIAM J. Appl. Math., 67 (2007), 937-951.
38. L. Shoda, D. Young, S. Ramanujan, C. Whiting, M. Atkinson, J. Bluestone, G. Eisenbarth, D. Mathis, A. Rossini, S. Campbell, R. Kahn and H. Kreuwel, A comprehensive review of interventions in the NOD mouse and implications for translation, Immunity, 23 (2005), 115-126.
39. X. Wang, Z. He and S. Ghosh, Investigation of the age-at-onset heterogeneity in type 1 diabetes through mathematical modeling, Math. Biosci., 203 (2006), 79-99.
40. Y. Zheng, H. Kreuwel, D. Young, L. Shoda, S. Ramanujan, K. Gadkar, M. Atkinson and C. Whiting, Applying predictive biosimulation to research in type 1 diabetes, Ann. N. Y. Acad. Sci., 1103 (2007), 45-62.
41. M. Pietropaolo, J. Surhigh, P. Nelson and G. Eisenbarth, Primer: immunity and autoimmunity, Diabetes, 57 (2008), 2872-2882.
42. J. Bach and D. Mathis, The NOD mouse, Res. Immunol., 148 (1997), 285-286.
43. M. Atkinson and E. Leiter, The NOD mouse modei of type 1 diabetes: as good as it gets, Nat. Med., 5 (1999), 601-604.
44. A. Rossini, R. Williams, J. Mordes, M. Appel and A. Like, Spontaneous diabetes in gnotobiotic BB/W rat, Diabetes, 28 (1979), 1031-1032.
45. A. Like, A. Butler, R. Williams, M. Appel, E. Weringer and A. Rossini, Spontaneous autoimmune diabetes mellitus in the BB rat, Diabetes, 31 (1982), 7-13.
46. J. SkyIer, C. Greenbaum, J. Lachin, E. Leschek, L. Rafkin-Mervis, P. Savage and L. Spain, Type 1 Diabetes TrialNet-an international collaborative clinical trials network, Ann. N.Y. Acad. Sci., 1150 (2008), 14-24.
47. M. von Herrath and G. Nepom, Animal models of human type 1 diabetes, Nat. Immunol., 10 (2009), 129-132.
48. A. De Gaetano, T. Hardy, B. Beck, E. Abu-Raddad, P. Palumbo, J. Bue-Valleskey and N. Porksen, Mathematical models of diabetes progression, Am. J. Physiol. Endocrinol. Metab., 295 (2008), E1462-E1479.
49. D. Finegood, L. Scaglia and S. Bonner-Weir, Dynamics of beta-cell mass in the growing rat pancreas estimation with a simple mathematical model, Diabetes, 44 (1995), 249-256.
50. F. Athanasius, M. Maree, R. Kublik, D. Finegood and L. Edelstein-Keshet, Modeling the onset of Type 1 diabetes: can impaired macrophage phagocytosis make the difference between health and disease? Phil. Trans. R. Soc. A., 364 (2006), 1267-1282.
51. W. Malaisse, F. Malaisse-Lagae and E. McCraw, Effects of thyroid function upon insulin secretion, Diabetes, 16 (1967), 643-646.
52. R. Hoffman, P. Vicini and C. Cobellli, Comparison of insulin sensitivity and glucos effectiveness determined by the one- and two-compartment-labeled minimal model in late prepubertal children and early adolescents, Metabolism, 51 (2002), 1582-1586.
53. K. Daugherty, Review of Insulin Therapy, J. Pharm. Pract., 17 (2004), 10-19.
54. R. Bergman, D. Finegood and M. Ader, Assessment of insulin sensitivity in vivo, Endocrine Rev., 6 (1985), 45-58.
55. G. Weir and S. Bonner-Weir, Five stages of evolving beta-cell dysfunction during progression to diabetes, Diabetes, 53 (2004), S16-S21.
56. A. Fernandes, L. King, Y. Guz, R. Stein, V. Wright and G. Teilelman, Differentation of new insulin-producing cells is induced by injury in adult pancreatic islets, Endocrin., 138 (1997), 1750-1762.
57. S. Bonner-Weir, L. Baxter, G. Schuppin and T. Smith, A second pathway for regeneration of adult exocrine and endocrine pancreas: A possible recapitulation of embryonic development, Diabetes, 42 (1993), 1715-1720.
58. S. Bonner-Weir, A. Inada, S. Yotoh, W. Li, T. Ave, E. Toschi and A. Sharma, Transdifferentiation of pancreatic ductal cells to endocrine beta-cells, Biochem. Soc. Trans., 36 (2008), 353-356.
59. I. Swenne, The role of glucose in the in-vitro regulation of cell cycle kinetics and proliferation of fetal pancreatic beta-cells, Diabetes, 31 (1982), 754-760.
60. M. Hoorens, A. Van de Casteele, G. Kloppel and D. Pipeleers, Glucose promotes survival of rat pancreatic beta-cells by activating synthesis of proteins which suppress a constitutive apoptotic program, J. Clin. Invest., 98 (1996), 1568-1574.
61. B. Efanova, S. Zaitsev, B. Zhivotovsky, M. Kohler, S. Efendic, S. Orrenius and P. Berggren, Glucose and tolbutamide induce apoptosis in pancreatic beta-cells, J. Biol. Chem., 273 (1998), 33501-33507.
62. G. Weir and S. Bonner-Weir, A dominant role for glucose in beta cell compensation of insulin resistance, J. Clin. Invest., 117 (2007), 81-83.
63. A. Jorns, A. Gunther, H. Hendrick, D. Wedekind, M. Tiedge and S. Lenzen, Immune cell infiltration, cyotkine expression, and beta-cell apoptosis during the development of type 1 Diabetes in the spontaneous diabetic LEW.1AR1/Ztm-iddm Rat, Diabetes, 54 (2005), 2041-2052.
64. E. Simpson, Special regulatory T-cell review: regulation of immune responses - examining the role of T cells, Immunology, 123 (2008), 13-16.
65. M. Donath and J. Ehses, Mechanisms of Beta-cell death in diabetes, Springer Japan, , 2008.
66. M. Pietropaolo, S. Yu, I. Libman, S. Pietropaolo, K. Riley, R. LaPorte, A. Drash, S. Mazumdar, M. Trueco and D. Becker, Cytoplasmic islet cell antibodies remain valuable in defining risk of progression to type 1 diabetes in subjects with other islet autoantibodies, Pediatr. Diabetes, 4 (2005), 184-192.
67. E. Gale and P. Bingley, Can we prevent IDDM? Diabetes, 42 (1993), 213-220.
68. P. Bingley, M. Christie, E. Bonifacio, R. Bonfanti, M. Shattock, M. Fonte, G. Bottazzo and E. Gale, Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives, Diabetes, 43 (1994), 1304-1310.
69. N. Maclaren, M. Lan, R. CoUtant, D. Schatz, J. Silverstein, A. Muir, M. ClareSalzler, J. She, J. Malone, S. Crockett, S. Schwartz, T. Quattrin, M. DeSilva, P. Vander Vegt, A. Notkins and J. Krischer, Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2b predict immune-mediated (Type 1) diabetes in relatives, J. Autoimmun., 12 (1999), 279-287.
70. M. Pietropaolo and G. Eisenbarth, Autoantibodies in human diabetes, Curr. Dir. Autoimmun., 4 (2001), 252-282.
71. M. Pietropaolo, D. Becker, R. LaPorte, J. Dorman, S. Riboni, W. Rudert, S. Mazumdar and M. Trueco, Progression to insulin-requiring diabetes in seronegative prediabetic subjects: The role of two HLA-DQ high risk haplotypes, Diabetologia, 45 (2002), 66-76.
72. J. Krischer, D. Cuthbertson, L. Yu, T. Orban, N. Maclaren, R. Jackson, W. Winter, D. Schatz, J. Palmer and G. Eisenbarth, Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes, J. Clin. Endocrinol. Metab., 88 (2003), 103-108.
73. U. Wiest-Ladenburger, R. Hartmann, U. Hartmann, K. Berling, B. Bohm and W. Richter, Combined analysis and single-step detection of GAD65 and IA2 autoantibodies can replace the histochemical islet cell antibody test, Diabetes, 46 (1997), 565-571.
74. M. Pietropaolo, M. Peakman, S. Pietropaolo, M. Zanone, T. Foley, D. Becker and M. Trueco, Combined analysis of GAD65 and ICA512(IA-2) autoantibodies in organ and non-organ specific autoimmune diseases confers high specificity for insulin-dependent diabetes mellitus, J. Autoimmun., 11 (1998), 1-10.
75. J. Skyler, Prediction and prevention of type 1 diabetes: progress, problems, and prospects, Clin. Pharmacol. Ther., 81 (2007), 768-771.
76. D. Homann and M. von Herrath, Regulatory T cells and type 1 diabetes, Clin. Immunol., 112 (2004), 202-209.
77. G. Bottazzo, A. Florin-Christensen and D. Doniach, Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies, Lancet, 2 (1974), 1279-1283.
78. J. Sosenko, J. Krischer, J. Palmer, J. Mahon, C. Cowie, C. Greenbaum, D. Cuthbertson, J. Lachin and J. Skyler, Diabetes Prevention Trial-Type 1 Study Group. A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1, Diabetes Care, 31 (2008), 528-533.
79. DPT, Effects of insulin in relatives of patients with type 1 diabetes mellitus, NEJM, 346 (2002), 1685-1691.
80. E. Gale, P. Bingley, C. Emmett and T. Collier, European Nicotinamide diabetes intervention trial: a randomised controlled trial of intervention before the onset of type 1 diabetes, Lancet, 20 (2004), 925-931.
81. M. von Herrath, S. Sanda and K. Herold, Type 1 diabetes as a relapsing-remitting disease, Nat. Rev. Immunol., 7 (2007), 988-994.
82. M. Tenconi, G. Devoti, M. Comelli, M. Pinon, A. Capocchiano, V. Calcaterra, G. Pretti and the Pavia T1DM Registry Group, Major childhood infectious diseases and other determinants associated with type 1 diabetes: A case-control study, Acta Diabet., 44 (2006), 14-19.
83. Z. Laron, Interplay between heredity and environment in the recent explosion of type 1 childhood diabetes mellitus, Am. J. Med. Gen., 115 (2002), 4-7.
84. J. Dorman and others, Risk factors for insulin-dependent diabetes. In Diabetes in America, National Institute of Diabetes and Digestive and Kidney Diseases, 1 (1995), 165-177.
85. T. Palosuo, J. Virtamo, R. Taylor, K. Aho, M. Puurunen and O. Vaarala, High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men. A nested case-control study, Thromb. Haemostasis, 78 (1997), 1178-1182.
86. H. Barmeier, D. McCulloch, J. Neifing, Warnock, R. Rajotte, J. Palmer and A. Lernmark, Risk for developing type 1 (insulin-dependent) diabetes mellitus and the presence of islet 64K antibodies, Diabetologia, 34 (1991), 727-733.
87. W. Riley, N. Maclaren, J. Krischer, R. Spillar, J. Silverstein, D. Schatz, S. Schwartz, J. Malone, S. Shah, C. Vadheim and J. Rotter, A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes, N. Engl. J. Med., 323 (1990), 1167-1172.
88. A. Ziegler, M. Hummel, M. Schenker and E. Bonifacio, Autoantibody appearance and risk for development of childhood diabetes in offspring parents with Type 1 diabetes. The 2-year analysis of the German BABYDIAB study, Diabetes, 48 (1999), 460-468.
89. J. Wenzlau, K. Juhl, L. Yu, O. Moua, S. Sarkar, P. Gottlieb, M. Rewers, G. Eisenbarth, J. Jensen, H. Davidson and J. Hutton, The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes, Proc. Natl. Acad. Sci. USA, 104 (2007), 17040-17045.